Is there an association between GNβ3-C825T genotype and lower functional gastrointestinal disorders?
Is there an association between GNβ3-C825T genotype and lower functional gastrointestinal disorders?
复制标题
DOI：
10.1053/j.gastro.2006.03.017
复制
发表时间：
2006-06-01
期刊：
影响因子：
29.4
通讯作者：
Zinsmeister, Alan R.
中科院分区：
文献类型：
--
作者：
Andresen, Viola;Camilleri, Michael;Zinsmeister, Alan R.
背景与目的：GN β 3影响大多数配体受体激活的G蛋白翻译。据报道，功能性消化不良（FD）与GN β 3基因中C825 T多态性的纯合基因型相关。目前尚不清楚GN β 3基因型是否与低功能胃肠疾病（FGID）有关。我们旨在比较不同GN β 3-CS25 T基因型在低FGID患者和健康对照组中的患病率，并测试这些遗传变异与肠易激综合征（IBS），功能性腹痛（FAP），低FGID-FD重叠和高躯体症状评分亚组的相关性。方法：对233例低FGID患者和152例健康对照者进行GN β 3-C825 T基因多态性分析。一项经验证的肠道问卷调查表征了FGID表型：82例IBS便秘，94例IBS腹泻，38例IBS交替性肠功能，19例FAP。使用罗马II标准，有JL 59例患者患有较低的FGID和重叠FD。回归分析评估了GN β 3基因型与低FGID的相关性，以及FGID和躯体症状评分的亚组。结果如下：GN β 3-C825 T基因型分布在健康对照组（50.7%CC，40.8%TC）和FGID较低的患者（8.6%TT，515%CC，40.8%TC和7.7%TT）之间相似。GN β 3-C825 T多态性与总体FGID较低或与包括IBS、FAP、FGID-FD重叠较低或躯体症状评分较高在内的单独症状亚组无显著相关性。结论：与报道的FD相关性相反，GN β 3-C825 T多态性与FGID较低、不同IBS或FAP表型或FGID-FD重叠较低无显著相关性。
Background & Aims: GN beta 3 influences G-protein translation of a majority of ligand-receptor activations. It has been reported that functional dyspepsia (FD) is associated with homozygous genotypes of the C825T polymorphism in the GN beta 3 gene. It is unknown whether the GN beta 3 genotype is associated with lower functional gastrointestinal disorders (FGID). We aimed to compare the prevalence of the different GN beta 3-CS25T genotypes in patients with lower FGID and healthy controls and to test the associations of these genetic variations with subgroups of irritable bowel syndrome (IBS), functional abdominal pain (FAP), lower FGID-FD overlap, and high somatic symptom scores. Methods: GN beta 3-C825T polymorphism was analyzed in DNA from blood samples of 233 patients with lower FGID and 152 healthy controls. A validated bowel questionnaire characterized the FGID phenotype: 82 with IBS constipation, 94 with IBS diarrhea, 38 with IBS alternating bowel function, and 19 with FAP. There were JL59 patients with lower FGID and overlap FD using Rome II criteria. Regression analyses assessed associations of the GN beta 3 genotypes with lower FGID as a group, and subgroups of FGID and somatic symptom scores. Results: GN beta 3-C825T genotype distributions were similar between healthy controls (50.7% CC, 40.8% TC) and patients with lower FGID (8.6% TT, 515% CC, 40.8% TC, and 7.7% TT). There were no significant associations of GN beta 3-C825T polymorphism with lower FGID overall or with the separate symptom subgroups including IBS, FAP, lower FGID-FD overlap, or high somatic symptom scores. Conclusions: In contrast to the reported association with FD, GN beta 3-C825T polymorphism is not associated significantly with lower FGID, with different IBS or FAP phenotypes, or lower FGID-FD overlap.